Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series
Our study underscores the rarity and potential severity of hematologic toxicities, underlining the need for heightened clinician awareness and the incorporation of hematologic guidance into oncologic practice. Although predictive biomarkers remain unvalidated, monitoring immune cell subsets or recognizing warning signals early on may facilitate diagnosis and improve prognosis.
Authors
- Emanuele Bruni (ORCID: https://orcid.org/0000-0001-9585-0486)
- Alessandra Frezzolini
- Maria Luigia Carbone (ORCID: https://orcid.org/0000-0002-3350-1210)
- Gabriele Piesco
- Cristina Maria Failla (ORCID: https://orcid.org/0000-0001-5991-8914)
- Federica De Galitiis
- Paolo Chesi
- Maria Cantonetti
- Sofia Verkhovskaia (ORCID: https://orcid.org/0009-0008-2599-807X)
- Rosa Falcone (ORCID: https://orcid.org/0000-0001-9679-4711)
- Paolo Marchetti (ORCID: https://orcid.org/0000-0001-5170-9579)
- Francesca Romana Di Pietro
Institutions
- Saint Camillus International University of Health and Medical Sciences (IT)
- Istituto Dermopatico dell'Immacolata (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fphar.2025.1717727
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute